291 related articles for article (PubMed ID: 18173954)
1. Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Kuusisto J; Andrulionyte L; Laakso M
Curr Atheroscler Rep; 2007 Oct; 9(4):274-80. PubMed ID: 18173954
[TBL] [Abstract][Full Text] [Related]
2. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Chinetti-Gbaguidi G; Staels B
Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Staels B; Fruchart JC
Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
5. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
Robinson E; Grieve DJ
Pharmacol Ther; 2009 Jun; 122(3):246-63. PubMed ID: 19318113
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
7. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
[TBL] [Abstract][Full Text] [Related]
9. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
Cheang WS; Tian XY; Wong WT; Huang Y
Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
[TBL] [Abstract][Full Text] [Related]
10. PPAR ligands: are they potential agents for cardiovascular disorders?
Balakumar P; Rose M; Singh M
Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
[TBL] [Abstract][Full Text] [Related]
11. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
[TBL] [Abstract][Full Text] [Related]
12. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
13. PPAR agonists and the metabolic syndrome.
Staels B
Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
Wagner N; Wagner KD
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768666
[TBL] [Abstract][Full Text] [Related]
15. Fibrates, glitazones, and peroxisome proliferator-activated receptors.
Lalloyer F; Staels B
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):894-9. PubMed ID: 20393155
[TBL] [Abstract][Full Text] [Related]
16. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis.
Li AC; Palinski W
Annu Rev Pharmacol Toxicol; 2006; 46():1-39. PubMed ID: 16402897
[TBL] [Abstract][Full Text] [Related]
18. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
Pershadsingh HA
Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
[TBL] [Abstract][Full Text] [Related]
19. PPARs and diabetes-associated atherosclerosis.
Calkin AC; Jandeleit-Dahm KA; Sebekova E; Allen TJ; Mizrahi J; Cooper ME; Tikellis C
Curr Pharm Des; 2007; 13(26):2736-41. PubMed ID: 17897018
[TBL] [Abstract][Full Text] [Related]
20. The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis.
Verma S; Szmitko PE
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):12B-17B. PubMed ID: 16498507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
